Inhibikase Therapeutics, Inc.

At Inhibikase, we are dedicated to developing novel treatments for Parkinson's disease that have the potential to halt disease progression and reverse functional loss. Learn more: https://bit.ly/3r80qLu

Inhibikase completed enrollment of its Phase 2 ‘201’ trial evaluating risvodetinib for treatment in untreated Parkinson’s patients in June of this year and anticipates reporting trial results in the fourth quarter of 2024. Learn more about the trial: https://bit.ly/3a44V0V

Growing evidence suggests Cellular Abelson Tyrosine Kinase (c-Abl) plays a central role in Parkinson’s Disease progression. Inhibikase is developing a novel c-able kinase inhibitor, risvodetinib (IkT-148009), that has the potential to halt disease progression and reverse functional loss. Learn more: https://bit.ly/34JNwrC

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure in the arteries of the lungs. Inhibikase submitted an IND to the FDA and plans to begin ramp-up of the Phase 2 702 trial of IkT-001Pro for PAH, subject to receipt of the Study May Proceed letter. https://bit.ly/3W60TKI

Inhibikase is dedicated to developing meaningful treatment options for patients with Parkinson’s Disease that could change the course of the disease in the body. Learn more here:

Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase, comments on the Company's second quarter financial results and recent period activity. For more info: https://bit.ly/46NlkQk

Inhibikase will host a conference call and webcast today at 8:00 a.m. ET to provide a corporate update and review the financial results for the second quarter ended June 30, 2024. Join the webcast here: https://bit.ly/3SI72uC

Inhibikase has reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments. The Company will host a conference call tomorrow, August 15, at 8:00 a.m. ET to discuss the results. https://bit.ly/46NlkQk

Pulmonary Arterial Hypertension, or PAH, is a rare disease of the pulmonary, or lung, microvasculature, characterized by hypertension that affects the functioning of the right-side of the heart, the side of the heart that sends and receives blood to and from the lungs.

Inhibikase will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. https://bit.ly/46DSVMz